Viracta Therapeutics (VIRX) Stock Forecast & Price Target

$0.22

0.00 (0.00%)

(As of 09/18/2024 ET)

Viracta Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 4 Analyst Ratings

Based on 4 Wall Street analysts who have issued ratings for Viracta Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a hold rating, and 3 have given a buy rating for VIRX.

Consensus Price Target

$5.50
2,405.69% Upside

High Forecast	$11.00
Average Forecast	$5.50
Low Forecast	$3.00

According to the 4 analysts' twelve-month price targets for Viracta Therapeutics, the average price target is $5.50. The highest price target for VIRX is $11.00, while the lowest price target for VIRX is $3.00. The average price target represents a forecasted upside of 2,405.69% from the current price of $0.22.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$5.50	$5.50	$6.50	$9.50
Forecasted Upside	2,405.69% Upside	889.88% Upside	642.64% Upside	589.66% Upside

Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)

Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.

Click here to see it because it’s a SHOCKER…

VIRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VIRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Viracta Therapeutics Stock vs. The Competition

Type	Viracta Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.77	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	2,405.69% Upside	1,007.90% Upside	7.93% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
8/16/2024	Leerink Partners 1 of 5 stars	Downgrade	Outperform ➝ Market Perform	$5.00 ➝ $3.00	+760.81%
8/15/2024	Royal Bank of Canada 4 of 5 stars	Lower Target	Outperform ➝ Outperform	$6.00 ➝ $4.00	+1,033.12%
5/23/2024	Oppenheimer 3 of 5 stars	Lower Target	Outperform ➝ Outperform	$13.00 ➝ $11.00	+1,345.45%
4/16/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00	+426.31%
8/15/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$10.00 ➝ $5.00	+259.71%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:23 AM ET.

VIRX Forecast - Frequently Asked Questions

What is Viracta Therapeutics' forecast for 2024?: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Viracta Therapeutics is $5.50, with a high forecast of $11.00 and a low forecast of $3.00.
Should I buy or sell Viracta Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viracta Therapeutics in the last year. There is currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VIRX shares.
Does Viracta Therapeutics's stock price have much upside?: According to analysts, Viracta Therapeutics's stock has a predicted upside of 889.88% based on their 12-month stock forecasts.
Has Viracta Therapeutics been downgraded by Wall Street analysts recently?: Over the previous 90 days, Viracta Therapeutics's stock had 1 downgrade by analysts.
What analysts cover Viracta Therapeutics?: Viracta Therapeutics has been rated by research analysts at Leerink Partners, and Royal Bank of Canada in the past 90 days.
Do Wall Street analysts like Viracta Therapeutics more than its competitors?: Analysts like Viracta Therapeutics less than other "medical" companies. The consensus rating score for Viracta Therapeutics is 2.75 while the average consensus rating score for "medical" companies is 2.77. Learn more on how VIRX compares to other companies.